{"id":948956,"date":"2026-04-03T16:09:42","date_gmt":"2026-04-03T20:09:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/"},"modified":"2026-04-03T16:09:42","modified_gmt":"2026-04-03T20:09:42","slug":"spyre-therapeutics-announces-grants-of-inducement-awards-10","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/","title":{"rendered":"Spyre Therapeutics Announces Grants of Inducement Awards"},"content":{"rendered":"
\n

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \u201cCompany\u201d or \u201cSpyre\u201d), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre\u2019s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the \u201c2018 Plan\u201d). The stock options were approved on April 1, 2026 and were material to each employee’s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n

The stock options were granted with a 10-year term and an exercise price equal to $48.90, the closing price per share of Spyre’s common stock as reported by Nasdaq on April 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1\/4th) of the shares subject to the respective options on the first anniversary of the employee\u2019s start date, and one-forty-eighth (1\/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.<\/p>\n

\n About Spyre Therapeutics<\/strong>\n <\/p>\n

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (\u201cIBD\u201d) and rheumatic diseases. Spyre’s pipeline includes investigational extended half-life antibodies targeting \u03b14\u03b27, TL1A, and IL-23.<\/p>\n

For more information, please visit http:\/\/spyre.com.<\/p>\n

\n For Investors<\/strong>
\n :<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \u201cCompany\u201d or \u201cSpyre\u201d), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre\u2019s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the \u201c2018 Plan\u201d). The stock options were approved on April 1, 2026 and were material to each employee’s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4). The … <\/p>\n

Continue reading “Spyre Therapeutics Announces Grants of Inducement Awards”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-948956","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSpyre Therapeutics Announces Grants of Inducement Awards - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spyre Therapeutics Announces Grants of Inducement Awards - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \u201cCompany\u201d or \u201cSpyre\u201d), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre\u2019s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the \u201c2018 Plan\u201d). The stock options were approved on April 1, 2026 and were material to each employee’s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4). The … Continue reading "Spyre Therapeutics Announces Grants of Inducement Awards"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-03T20:09:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzE3OSM3NTE2OTI0IzIyOTQ4MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spyre Therapeutics Announces Grants of Inducement Awards\",\"datePublished\":\"2026-04-03T20:09:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/\"},\"wordCount\":289,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzE3OSM3NTE2OTI0IzIyOTQ4MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/\",\"name\":\"Spyre Therapeutics Announces Grants of Inducement Awards - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzE3OSM3NTE2OTI0IzIyOTQ4MTM=\",\"datePublished\":\"2026-04-03T20:09:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzE3OSM3NTE2OTI0IzIyOTQ4MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzE3OSM3NTE2OTI0IzIyOTQ4MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-grants-of-inducement-awards-10\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spyre Therapeutics Announces Grants of Inducement Awards\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spyre Therapeutics Announces Grants of Inducement Awards - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/","og_locale":"en_US","og_type":"article","og_title":"Spyre Therapeutics Announces Grants of Inducement Awards - Market Newsdesk","og_description":"WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \u201cCompany\u201d or \u201cSpyre\u201d), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre\u2019s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the \u201c2018 Plan\u201d). The stock options were approved on April 1, 2026 and were material to each employee’s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4). The … Continue reading \"Spyre Therapeutics Announces Grants of Inducement Awards\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-03T20:09:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzE3OSM3NTE2OTI0IzIyOTQ4MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spyre Therapeutics Announces Grants of Inducement Awards","datePublished":"2026-04-03T20:09:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/"},"wordCount":289,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzE3OSM3NTE2OTI0IzIyOTQ4MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/","name":"Spyre Therapeutics Announces Grants of Inducement Awards - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzE3OSM3NTE2OTI0IzIyOTQ4MTM=","datePublished":"2026-04-03T20:09:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzE3OSM3NTE2OTI0IzIyOTQ4MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzE3OSM3NTE2OTI0IzIyOTQ4MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-grants-of-inducement-awards-10\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spyre Therapeutics Announces Grants of Inducement Awards"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/948956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=948956"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/948956\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=948956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=948956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=948956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}